[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-329224-105":59,"doc-detail-329224-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","thrombosis-in-myeloproliferative-neoplasms-a-viewpoint-on-its-impact-on-myelofibrosis-mortality-and-solid-tumors","Thrombosis in myeloproliferative neoplasms - a viewpoint on its impact on myelofibrosis, mortality, and solid tumors","","Review article synthesizing large patient-database analyses in myeloproliferative neoplasms (MPNs) to evaluate how thrombosis influences mortality, disease progression, and secondary cancers. Despite treatment advances, arterial and venous thrombosis rates remain challenging. Thrombotic events are linked to a more aggressive disease course, including myelofibrosis progression and higher mortality. Inflammatory biomarkers such as neutrophil-to-lymphocyte ratio associate thrombosis with risk and suggest a shared inflammatory pathway across cardiovascular and cancer incidence, often in younger patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/thrombosis-in-myeloproliferative-neoplasms-a-viewpoint-on-its-impact-on-myelofibrosis-mortality-and-solid-tumors/329224/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/thrombosis-in-myeloproliferative-neoplasms-a-viewpoint-on-its-impact-on-myelofibrosis-mortality-and-solid-tumors/329224.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this viewpoint on thrombosis in MPNs?","Question",{"text":113,"@type":114},"To clarify current clinical evidence on key events showing how thrombosis impacts disease severity and identifies potential therapeutic targets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do thrombosis events relate to disease progression and outcomes in MPN patients?",{"text":118,"@type":114},"They are associated with a more aggressive disease course, including myelofibrosis progression and increased mortality.",{"name":120,"@type":111,"acceptedAnswer":121},"Which biomarkers and pathways are linked to thrombosis and cancer risk in this review?",{"text":122,"@type":114},"Inflammatory biomarkers such as neutrophil-to-lymphocyte ratio (NLR) are associated with aggressiveness and connect thrombosis to secondary cancer risk, suggesting a common inflammatory pathway.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},329224,1790174742,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Blood Cancer [Journal](Journal www.nature.com/bcj)[ www.nature.com/bcj](Journal www.nature.com/bcj)  \nREVIEW ARTICLE OPEN   \nThrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors  \nTiziano Barbui 1 ✉ , Arianna Ghirardi1, Alessandra Carobbio 2, Valerio De Stefano 3,4, Alessandro Rambaldi 5,6  \n,  \nAyalew Tefferi 7 and Alessandro M. Vannucchi 8  \n© The Author(s) 2024  \n\n|  | This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC) . Despite advances, the current incidence of arterial and venous thrombosis remains a challenge. These events appear to signal a more aggressive disease course, as evidenced by their association with myelofibrosis progression and mortality using multistate models and time-dependent multivariable analysis. Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), are associated with the aggressiveness of polycythemia vera (PV) and essential thrombocythemia (ET), linking thrombosis to SC risk. This suggests a common inflammatory pathway likely influencing cardiovascular disease and cancer incidence. Notably, this is observed more frequently in younger patients, likely due to prolonged exposure to MPN and environmental inflammatory triggers. These data underscore the need for new studies to validate these associations, delineate the sequence of events, and identify therapeutic |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| targets to mitigate thrombotic events and potentially improve overall patient outcomes in MPN. |  |  |\n|  | Blood Cancer Journal (2024)14:188; [https://doi.org/10.1038/s41408-024-01](https://doi.org/10.1038/s41408-024-01)169-6 |  |\n|  |  |  |\n\nINTRODUCTION  \nThe classic chronic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [1] . These disorders are characterized by a high incidence of arterial and venous thrombotic events [2, 3], potential progression to post-PV and post-ET myelofibrosis [4], and acute leukemia [5] . Understanding of the pathophysiology of MPNs has improved significantly with the identification of common genetic mutations, most notably the JAK2 V617F mutation, which is found in over 95% of PV and approximately 60–70% of ET and PMF cases [1, 6, 7] . Therapy is aimed at reducing the incidence of thrombosis, which is a major cause of death and severe disability in some patients [8, 9] .  \nRecent reports suggest that the occurrence of thrombosis, particularly arterial events during the course of PV and ET, may pose additional risks such as progression to myelofibrosis [10, 11], increased mortality [10–13], and the development of secondary solid tumors [14, 15] . These risks arise from disease-related clonal hematopoiesis and subsequent chronic systemic inflammation, leading to thrombosis and genetic instability.  \nIn our large databases of patients with MPN, we investigated the incidence and risk factors of thrombosis that may explain this association, culminating in an increased risk of mortality. This Viewpoint presents our findings with the goal of clarifying the current clinical evidence regarding key events that influence  \ndisease severity and may serve as potential therapeutic targets. This work is not intended to be a systematic review of the literature, but rather a perspective to stimulate interest and further research into these critical issues.  \nRATES OF THROMBOSIS IN MPNS  \nDespite recommended treatments, thrombosis remains a significant challenge for patients diagnosed with MPNs today. It often heralds the diagnosis of MPN in approximately 20% of cases, with a persistent risk observed at subsequent follow-up. A recent study of 9429 MPN patients and 35,820 matched controls diagnosed betwee","cbCaiixdmpNt2uRe","https://ap.wps.com/l/cbCaiixdmpNt2uRe","pdf",1215581,"English","# Introduction\n# Rates of thrombosis in MPNs","[{\"question\":\"What is the main purpose of this viewpoint on thrombosis in MPNs?\",\"answer\":\"To clarify current clinical evidence on key events showing how thrombosis impacts disease severity and identifies potential therapeutic targets.\"},{\"question\":\"How do thrombosis events relate to disease progression and outcomes in MPN patients?\",\"answer\":\"They are associated with a more aggressive disease course, including myelofibrosis progression and increased mortality.\"},{\"question\":\"Which biomarkers and pathways are linked to thrombosis and cancer risk in this review?\",\"answer\":\"Inflammatory biomarkers such as neutrophil-to-lymphocyte ratio (NLR) are associated with aggressiveness and connect thrombosis to secondary cancer risk, suggesting a common inflammatory pathway.\"}]","Thrombosis in myeloproliferative neoplasms - a viewpoint on its impact on myelofibrosis, mortality, and solid tumors | PDF",1789983160]